Therapeutic peptides under the spotlight

EBR - European Biopharmaceutical Review

Volumn , Issue WINTER, 2005, Pages 88-93

  Pichereau, Catherine ^a,b,c   Allary, Claude ^a,d,e,f,g  

^a Bionest Partners

^b Robertson Stephens   (United Kingdom)

^c Bank of America Securities   (United Kingdom)

^d SANOFI   (France)

^e Park Davis ^*  (South Africa)

^f GLAXOSMITHKLINE   (United Kingdom)

^g ISO Health Care Group

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; COGNIS; COSMETIC; DESMOPRESSIN; ENFUVIRTIDE; EPTIFIBATIDE; GENERIC DRUG; GLATIRAMER; GOSERELIN; HIRULOG; LEUPRORELIN; LIPOTEC; LYPRESSIN; PEPTIDE; SALCATONIN; SEDERMA; SOMATOSTATIN DERIVATIVE;

ARTICLE; BIOTECHNOLOGY; CLINICAL TRIAL; CONTRACT; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; DRUG TARGETING; HUMAN; PEPTIDE SYNTHESIS; PROTEIN BINDING; PROTEIN TARGETING; PROTEOMICS; RISK REDUCTION; STATISTICAL SIGNIFICANCE;

EID: 33645055395     PISSN: 1364369X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)